ReviewFuture cardiology2017
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Review in Future cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 3 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Exposure to perfluoroalkyl and polyfluoroalkyl substances and pediatric obesity: a systematic review and meta-analysis.International journal of obesity (2005) · 2024Pooled it
- Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Early-Life Exposure to Per- and Poly-Fluorinated Alkyl Substances and Growth, Adiposity, and Puberty in Children: A Systematic Review.Frontiers in endocrinology · 2021Pooled it
- Leveraging Advanced AI Frameworks for Dual PPAR α/γ Agonist Discovery in Alzheimer's Disease.ACS chemical neuroscience · 2026Review
- IntegrativeNutrients · 2026Article
- Regulatory risk loci link disrupted androgen response to the pathophysiology of polycystic ovary syndrome.Journal of the Endocrine Society · 2026Article
- Discrimination of Steatotic and Non-Steatotic Chemicals Through Transcriptome Analysis in Primary Human Hepatocytes.International journal of molecular sciences · 2026Article
- A Novel Role for the Small Molecule Cinnamaldehyde in Protecting AgainstAntioxidants (Basel, Switzerland) · 2026Article
- Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Accumulation of newly synthesized docosahexaenoic acid plays an essential role in heart regeneration.Protein & cell · 2026Article
- Perfluorooctanoic acid disrupts hepatic metabolism in the developing chicken embryo.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Association between Maternal Exposure to Per- and Polyfluoroalkyl Substances and Childhood Growth Trajectories up to 4 Years of Age: The Japan Environment and Children's Study.Environmental science & technology · 2025Article
- Changes in Apolipoprotein A1-Associated Proteomic Composition After Pioglitazone Treatment Versus Weight Loss.International journal of molecular sciences · 2025Article
- Selenium Supplementation Mitigates Copper-Induced Systemic Toxicity via Transcriptomic Reprogramming and Redox Homeostasis in Mice.Foods (Basel, Switzerland) · 2025Article
- Maternal serum and placental metabolomes in association with prenatal exposure to per- and polyfluoroalkyl substances and their relevance to child neurodevelopment in an ASD-enriched cohort.Environmental pollution (Barking, Essex : 1987) · 2025Article
- Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment.JHEP reports : innovation in hepatology · 2025Article
- Direct regulation of Per2 by Roraa: insights into circadian and metabolic interplay in zebrafish.Cellular and molecular life sciences : CMLS · 2025Article
- Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Unraveling PPARβ/δ nuclear receptor agonistsRSC advances · 2025Article
- PPARs Activity Affects the Hatchability Through Lipid Metabolism Regulation in Silkworm,Biomolecules · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The PPARs are a subfamily of three ligand-inducible transcription factors, which belong to the superfamily of nuclear hormone receptors. In mammals, the PPAR subfamily consists of three members: PPAR-α, PPAR-β/δ and PPAR-γ. PPARs control the expression of a large number of genes involved in metabolic homeostasis, lipid, glucose and energy metabolism, adipogenesis and inflammation. PPARs regulate a large number of metabolic pathways that are implicated in the pathogenesis of metabolic diseases such as metabolic syndrome, Type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disease. The aim of this review is to provide up-to-date information about the biochemical and metabolic actions of PPAR-β/δ and PPAR-γ, the therapeutic potential of their agonists currently under clinical development and the cardiovascular disease outcome of clinical trials of PPAR-γ agonists, pioglitazone and rosiglitazone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.